Direct ligand for ERBB3 and ERBB4 tyrosine kinase receptors. Concomitantly recruits ERBB1 and ERBB2 coreceptors, resulting in ligand-stimulated tyrosine phosphorylation and activation of the ERBB receptors. Perform diverse functions such as inducing growth and differentiation of epithelial, glial, neuronal, and skeletal muscle cells; inducing expression of acetylcholine receptor in synaptic vesicles during the formation of the neuromuscular junction; stimulating lobuloalveolar budding and milk production in the mammary gland and inducing differentiation of mammary tumor cells; stimulating Schwann cell proliferation; implication in the development of the myocardium such as trabeculation of the developing heart.
Binds to ERBB4 and ERBB3. Acts as a ligand for integrins and binds (via EGF domain) to integrins ITGAV:ITGB3 or ITGA6:ITGB4. Its binding to integrins and subsequent ternary complex formation with integrins and ERRB3 are essential for NRG1-ERBB signaling (By similarity).
Induces the phosphorylation and activation of MAPK3/ERK1, MAPK1/ERK2 and AKT1, and ligand-dependent ERBB4 endocytosis is essential for the NRG1-mediated activation of these kinases in neurons (By similarity)
The cytoplasmic domain interacts with the LIM domain region of LIMK1 (By similarity). Forms a ternary complex with ERBB3 and ITGAV:ITGB3 or ITGA6:ITGB4 (By similarity). Interacts with NRDC and BACE1 (PubMed:19935654)
The cytoplasmic domain may be involved in the regulation of trafficking and proteolytic processing. Regulation of the proteolytic processing involves initial intracellular domain dimerization (By similarity)
ERBB receptor binding is elicited entirely by the EGF-like domain
| Cancer Type | Mutation Percentage |
|---|---|
| Central Nervous System Astrocytoma Grade Iv | 1.42% |
| Lung Adenocarcinoma | 3.05% |
| Lung Small Cell Carcinoma | 1.48% |
| Lung Squamous Cell Carcinoma | 1.77% |
| Oesophagus Adenocarcinoma | 14.24% |
| Oesophagus Squamous Cell Carcinoma | 1.88% |
| Pancreas Ductal Carcinoma | 2.03% |
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to NRG1, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 32
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT04410653 | Metastatic and Locally Advanced NRG1-rearranged Malignancies | Afatinib in Advanced NRG1-Rearranged Malignancies | PHASE2 | COMPLETED |
| NCT07221513 | HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension | Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension | PHASE2 | RECRUITING |
| NCT01075373 | Schizophrenia | A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations | N/A | UNKNOWN |
| NCT04790695 | Metastatic Pancreatic Cancer | Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab | PHASE2 | COMPLETED |
| NCT03805841 | NSCLC, Stage IV, NSCLC Stage IIIB, NSCLC, Stage IIIC, NSCLC, Recurrent, EGFR Exon 20 Insertion Mutation, HER2-activating Mutation, ERBB Fusion, NRG1 Fusion | Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions | PHASE2 | TERMINATED |
| NCT05919537 | Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | PHASE1 | ACTIVE_NOT_RECRUITING |
| NCT05107193 | Solid Tumors | Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors) | N/A | NO_LONGER_AVAILABLE |
| NCT01097460 | Breast Neoplasms | MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer | PHASE1 | COMPLETED |
| NCT02538627 | Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | PHASE1 | TERMINATED |
| NCT00730470 | Advanced Solid Tumors | Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors | PHASE1 | COMPLETED |